Syneron Medical — Merger or Acquisition (September 2009)
12 slides from Syneron Medical's merger presentation, Sep 23, 2009
Slide 1: Creating a Leading Global Aesthetic Device Company
Exhibit 99.1 CREATING A LEADING GLOBAL AESTHETIC DEVICE COMPANY September 2009 SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS Statements in this document regarding the proposed transaction between Candela Corporation and Syneron Medical Ltd., including, without limitation, the expected timetable for com
Slide 2: Regulation FD and Important Additional Information
In addition, the statements in this document reflect the expectations and beliefs of Candela Corporation and/or Syneron Medical Ltd. as of the date of this document. Candela Corporation and Syneron Medical Ltd. anticipate that subsequent events and developments will cause their expectations and beli
Slide 3: Investment Highlights
Lou Scafuri Chief Executive Officer of Syneron Gerard Puorro Chief Executive Officer of Candela Fabian Tenenbaum Chief Financial Officer of Syneron 3 INVESTMENT HIGHLIGHTS Combination of Syneron and Candela creates a leading global aesthetic device company Comprehensive product portfolio Syneron’s p
Slide 4: Transaction Overview
4 TRANSACTION OVERVIEW Candela shareholders will receive 0.2911 ordindary shares of Syneron for each share of Candela common stock Syneron to issue 6.7 million shares Represents $2.84 per share considerations—51% premium to prior close(1) Total consideration of approximately $65 million(1) Fixed Exc
Slide 5: Attractive Market Opportunity
6.4 Favorable demographics Baby boomers still turning 50 6.0 70% of aesthetic procedures patients earn >$50,000 annually Deteriorating business model for physicians 4.0 under pressure from insurance Safer and easier-to-use technology opens up market to emerging medical specialties and 2.0 non-medica
Slide 6: Comprehensive Product Portfolio
COMPREHENSIVE PRODUCT PORTFOLIO Body Treatments Facial Treatments Body Contouring Fractional skin Treatment Cellulite Reduction Ablative Non-Ablative Laser-Assisted Lipolysis Wrinkle Reduction Hair Removal Skin Rejuvenation Leg Veins / Vascular Skin Tightening Tattoo / Pigment Removal Acne Treatment
Slide 7: Candela Recent Product Launches
New single-use disposable filter VelaShape II: Second Generation System Cleared by FDA for circumferential reduction Clinical trial: Reduction of up to 3 inches Requires only 4 treatments to achieve significant cellulite and circumferential reduction Disposable applicators (specific for treatment ar
Slide 8: Advantages of elôs Technology
Combination of light, conducted RF and surface cooling Light preheats target and increases its conductivity RF selectively heats targets which were preheated by light Light Selectivity Strongly scattered and reflected by skin Maximum skin penetration: 2–3 mm RF Heats up everything No selectivity No
Slide 9: Global Distribution Footprint
12 GLOBAL DISTRIBUTION FOOTPRINT Candela Syneron Combined + = 13 BALANCED PENETRATION OF KEY CUSTOMER SEGMENTS Segment #Worldwide Combined Medical Professionals “Core” (Dermatologists 50,000 20%–25%* 58%* 55%* and plastic surgeons) “Non -Core” (GPs, Ob 400,000 75%–80%* 32%* 45%* Gyn, Internists, Med
Slide 10: Well Positioned for Growth
Premium Aestheticians / Non -Med Spa Ch ains 500,000 Total Global Addressable M arket ~1,000,000 _____________ Source: Addressable market based on management assessment * US market data only 14 WELL POSITIONED FOR GROWTH Momentum from 6 major platform launches in last 18 months Body shaping product
Slide 11: Financial Strength
FINANCIAL STRENGTH Leadership* (Ranked by TTM Revenue) Revenue ($MM) 1. Syneron / Candela $186 2. Solta 107 3. Cynosure 99 4. Palomar 71 5. Cutera 63 6 . Iridex 45 $240 million cash, no debt Recent dramatic operating expense reductions given macroeconomic conditions Recurring revenue from service an
Slide 12: Syneron / Candela merger to be completed by year-end 2009
Meaningful recurring revenue in future through service and consumables Syneron / Candela merger to be completed by year-end 2009 17 18
Syneron Medical — Merger or Acquisition (September 2009) on 6ix